Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €1.26 EUR
Change Today +0.112 / 9.71%
Volume 3.2K
RYIN On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 4:50 AM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

sunesis pharmaceuticals inc (RYIN) Snapshot

Open
€1.27
Previous Close
€1.15
Day High
€1.28
Day Low
€1.16
52 Week High
08/28/14 - €6.47
52 Week Low
07/27/15 - €0.78
Market Cap
92.3M
Average Volume 10 Days
3.2K
EPS TTM
--
Shares Outstanding
73.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SUNESIS PHARMACEUTICALS INC (RYIN)

Related News

No related news articles were found.

sunesis pharmaceuticals inc (RYIN) Related Businessweek News

No Related Businessweek News Found

sunesis pharmaceuticals inc (RYIN) Details

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome. Sunesis Pharmaceuticals, Inc. has a collaboration agreement with Biogen Idec to discover, develop, and commercialize small molecule inhibitors of the human protein Raf kinase; and licensing agreements with Millennium to provide worldwide license to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. The company was founded in 1998 and is headquartered in South San Francisco, California.

39 Employees
Last Reported Date: 03/12/15
Founded in 1998

sunesis pharmaceuticals inc (RYIN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $488.1K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $390.1K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $420.9K
Compensation as of Fiscal Year 2014.

sunesis pharmaceuticals inc (RYIN) Key Developments

Sunesis Pharmaceuticals, Inc. - Special Call

To discuss the regulatory updates from its interactions with the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) regarding a potential path toward marketing authorization for vosaroxin as a treatment for acute myeloid leukemia (AML) in Europe and the United States

Sunesis Pharmaceuticals, Inc. Pharmaceuticals Announces Regulatory Update

Sunesis Pharmaceuticals, Inc. announced regulatory updates from its interactions with the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) regarding a potential path toward marketing authorization for vosaroxin as a treatment for acute myeloid leukemia (AML) in Europe and the United States. With respect to Europe, the company recently met separately with the Rapporteur (United Kingdom) and Co-Rapporteur (Netherlands) assigned to provide advice and guide the company through the Marketing Authorization Application (MAA) process. Based on these substantive discussions, the company was encouraged to proceed with an MAA filing for the indication of relapsed/refractory AML in patients age 60 years and older, a population with the greater medical need and for whom the greater benefit was observed in the vosaroxin/cytarabine treatment arm of VALOR, the company's pivotal Phase 3 study of vosaroxin and cytarabine in adult patients with relapsed or refractory AML. With respect to the United States, after conducting additional safety and efficacy analyses, the company recently met with the FDA. In light of not reaching statistical significance on the protocol-defined primary analysis of overall survival, Sunesis was informed that the Agency did not support a filing and encouraged the company to provide additional clinical evidence to support a future NDA submission. Based on feedback from European and U.S. regulators, the company will place near-term focus on the MAA filing, which it will work to complete as expeditiously as possible, and will evaluate and refine its plan to gain marketing approval in the U.S.

Sunesis Pharmaceuticals, Inc.(NasdaqCM:SNSS) dropped from Russell 2000 Index

Sunesis Pharmaceuticals, Inc. will be removed from Russell 2000 Index

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RYIN:GR €1.26 EUR +0.112

RYIN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
NeurogesX Inc $0.0060 USD 0.00
POZEN Inc $11.70 USD -0.475
View Industry Companies
 

Industry Analysis

RYIN

Industry Average

Valuation RYIN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.2x
Price/Book 5.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUNESIS PHARMACEUTICALS INC, please visit www.sunesis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.